One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   NGS-based RNA-seq Market

[ 英語タイトル ] NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022


Product Code : MNMHC00108264
Survey : MarketsandMarkets
Publish On : February, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

The global NGS-based RNA-seq market is projected to reach USD 2.65 billion by 2022 from USD 1.05 billion in 2017, at a CAGR of 20.2%. Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the NGS-based RNA-seq market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market.

Market Segments
In 2016, the sequencing platforms and consumables segment is expected to account for the largest share of the market. The data analysis, storage, and management is expected to register the highest growth rate owing to its development of more efficient data analysis solutions and growing computational capabilities of data analytics providers. Research centers and academic & government institutes segment accounted for the largest share of the global market in 2016 due to the increasing focus of market players on providing efficient RNA-seq products & services for research applications and the growing number of government funding programs. However, the hospitals and clinics segment is expected to register the highest growth due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-seq market owing to the technological advantages of expression profiling applications.

Largest and Fastest Geographical Market
Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe and Asia-Pasific. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, owing to focus on R&D activities and the low cost of NGS products & services in this region.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type - Tier 1 – 33%, Tier 2 – 50% and Tier 3 – 17%
• By Designation – C level – 35%, Director level – 25%, Others – 40%
• By Region – North America - 24%, Europe – 19%, APAC – 33%, RoW – 24%

Growth Strategies
The global NGS-based RNA-seq market is highly competitive, with a large number of global and local players. In 2016, the market was dominated by Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.). Product launches, agreements, and partnerships were the major strategies adopted by market players to achieve growth in the market.

Research Coverage
This report studies the NGS-based RNA-seq market based on product & service, application, technology, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
From an insights perspective, this research report has focused on various levels of analysis—industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the NGS-based RNA-seq market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios and services offered by the major players in the NGS-based RNA-seq market. The report analyzes the NGS-based RNA-seq market based on product & service, application, technology, end user, and region

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the NGS-based RNA-seq market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various NGS-based RNA-seq products and services across geographies

• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-seq market

• Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the NGS-based RNA-seq market

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKET SCOPE 15
1.3.1 MARKETS COVERED 15
1.3.2 GEOGRAPHIC SCOPE 15
1.3.3 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 16
1.5 LIMITATIONS 16
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH METHODOLOGY STEPS 18
2.2 RESEARCH DESIGN 19
2.3 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 20
2.3.1 SECONDARY RESEARCH 20
2.3.1.1 Key Data from Secondary Sources 20
2.3.2 PRIMARY DATA 21
2.3.2.1 Key Data from Primary Sources 22
2.3.2.2 Key Industry Insights 23
2.4 MARKET SIZE ESTIMATION 24
2.4.1.1 Bottom-up approach 24
2.4.1.2 Top-down approach 25
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.6 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
3.1 INTRODUCTION 28
4 PREMIUM INSIGHTS 33
4.1 NGS-BASED RNA-SEQ MARKET OVERVIEW 33
4.2 NGS-BASED RNA-SEQ MARKET GROWTH RATE, BY TECHNOLOGY, 2017 VS. 2022 (USD MILLION) 33
4.3 NGS-BASED RNA-SEQ MARKET, BY APPLICATION AND REGION, 2017 (USD MILLION) 34
4.4 NGS-BASED RNA-SEQ MARKET, BY END USER, 2017 VS. 2022 34
4.5 GEOGRAPHICAL SNAPSHOT OF THE NGS-BASED RNA-SEQ MARKET 35

5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
5.2.1 DRIVERS 38
5.2.1.1 Advantages of RNA-Seq over microarray technology 38
5.2.1.2 Technological advancements in RNA-Seq products 38
5.2.1.3 Increasing number of RNA-Seq grants 39
5.2.1.4 Increasing number of research activities involving RNA-Seq 40
5.2.1.5 Rapid growth in precision medicine 41
5.2.2 RESTRAINTS 41
5.2.2.1 Lack of skilled professionals 41
5.2.2.2 Standardization concerns of RNA-Seq in diagnostic testing 41
5.2.3 OPPORTUNITIES 42
5.2.3.1 Increasing applications of RNA-Seq in research 42
5.2.3.1.1 Cancer research 42
5.2.3.1.2 Agricultural research 42
5.2.4 CHALLENGES 43
5.2.4.1 Storage & interpretation of sequencing data 43
5.2.4.2 Analysis of RNA-Seq data for detection of novel transcripts 44
5.3 INDUSTRY TRENDS 44
5.3.1 GROWING NUMBER OF STRATEGIC PARTNERSHIPS AND COLLABORATIONS 44
5.3.2 INCREASING NUMBER OF CONFERENCES AND WORKSHOPS RELATED TO RNA-SEQ 45
6 GLOBAL NGS-BASED RNA SEQUENCING MARKET, BY PRODUCT & SERVICE 46
6.1 INTRODUCTION 47
6.1.1 SAMPLE PREPARATION 49
6.1.1.1 SAMPLE PREPARATION, BY WORKFLOW STEP 50
6.1.1.1.1 Fragmentation, end repair, and size selection 51
6.1.1.1.2 Library preparation and target enrichment 51
6.1.1.1.3 Quality control 52
6.1.1.2 SAMPLE PREPARATION, BY METHOD 52
6.1.1.2.1 Manual sample preparation 52
6.1.1.2.2 Microfluidic sample preparation 53
6.1.1.2.3 Robotic liquid handling sample preparation 53
6.1.2 SEQUENCING PLATFORMS AND CONSUMABLES 54
6.1.3 SEQUENCING SERVICES 55
6.1.4 DATA ANALYSIS, STORAGE, AND MANAGEMENT 56

7 GLOBAL NGS-BASED RNA SEQUENCING MARKET, BY TECHNOLOGY 58
7.1 INTRODUCTION 59
7.2 SEQUENCING BY SYNTHESIS 61
7.3 ION SEMICONDUCTOR SEQUENCING 62
7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING 63
7.5 NANOPORE SEQUENCING 64
8 GLOBAL NGS-BASED RNA SEQUENCING MARKET, BY APPLICATION 66
8.1 INTRODUCTION 67
8.2 EXPRESSION PROFILING ANALYSIS 68
8.3 SMALL RNA SEQUENCING 70
8.4 DE NOVO TRANSCRIPTOME ASSEMBLY 72
8.5 VARIANT CALLING AND TRANSCRIPTOME EPIGENETICS 74
9 GLOBAL NGS-BASED RNA SEQUENCING MARKET, BY END USER 76
9.1 INTRODUCTION 77
9.2 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 78
9.3 HOSPITALS & CLINICS 79
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 80
9.5 OTHER END USERS 81
10 GLOBAL NGS-BASED RNA SEQUENCING MARKET, BY REGION 82
10.1 INTRODUCTION 83
10.2 NORTH AMERICA 84
10.2.1 U.S. 88
10.2.2 CANADA 89
10.3 EUROPE 90
10.4 ASIA-PACIFIC 93
10.5 REST OF THE WORLD 98
11 COMPETITIVE LANDSCAPE 102
11.1 BUSINESS OVERVIEW 102
11.2 VENDOR INCLUSION CRITERIA 102
11.3 VENDOR DIVE 102
11.3.1 VANGUARDS 102
11.3.2 INNOVATORS 103
11.3.3 DYNAMIC PLAYERS 103
11.3.4 EMERGING PLAYERS 103

11.4 COMPETITIVE BENCHMARKING 104
11.4.1 PRODUCT OFFERING (FOR ALL 25 COMPANIES) 104
11.4.2 BUSINESS STRATEGY (FOR ALL 25 COMPANIES) 105
*Top 25 companies analyzed for this study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies (U.K.), PerkinElmer, Inc. , (U.S.), QAIGEN N.V. (Germany), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies (U.S.), Bio-Rad Laboratories, Inc. (U.S.), GATC Biotech AG (Germany), Macrogen, Inc. (South Korea), Eurofins Scientific (Luxembourg), BGI (China), Takara Holdings Inc. (Japan), Cofactor Genomics, Inc. (U.S.), Otogenetics Corporation (U.S.), NuGEN Technologies Inc. (U.S.), Hamilton Company (U.S.), Intrexon Corp. (U.S.), 10x Genomics, Inc. (U.S.), Personalis Inc. (U.S.), GENEWIZ, Inc. (U.S.), MedGenome Inc. (U.S.), Novogene Corporation (China), and Biomatters Ltd. (New Zealand)
12 COMPANY PROFILES 106
(OVERVIEW, PRODUCTS AND SERVICES, FINANCIALS, STRATEGY & DEVELOPMENT)*
12.1 ILLUMINA, INC. 106
12.2 THERMO FISHER SCIENTIFIC INC. 111
12.3 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 115
12.4 QAIGEN N.V. 118
12.5 F. HOFFMANN-LA ROCHE AG 122
12.6 AGILENT TECHNOLOGIES, INC. 125
12.7 BGI (BEIJING GENOMICS INSTITUTE) 128
12.8 OXFORD NANOPORE TECHNOLOGIES, LTD 131
12.9 PERKINELMER, INC. 133
12.10 EUROFINS SCIENTIFIC 136
12.11 GATC BIOTECH AG 139
12.12 MACROGEN, INC. 142
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
13 APPENDIX 145
13.1 DISCUSSION GUIDE 145
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 149
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 151
13.4 AVAILABLE CUSTOMIZATIONS 151
13.5 RELATED REPORTS 152
13.6 AUTHOR DETAILS 153

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+